Literature DB >> 6626434

Quinine disposition kinetics.

N J White, P Chanthavanich, S Krishna, C Bunch, K Silamut.   

Abstract

Intravenous quinine dihydrochloride (5 mg kg-1 over 5 min) was given to seven healthy male volunteers. There were minor subjective symptoms in all subjects but no significant changes in pulse or blood pressure. There was significant prolongation of the electrocardiographic QRS and rate corrected QT intervals which was greatest between 1 and 4 min after completion of the quinine infusion. Values then returned towards baseline. Plasma concentrations of quinine were measured spectrophotofluorimetrically after benzene extraction. Peak plasma concentrations (mean +/- 1 s.d.) after the infusion were 5.1 +/- 1.3 mg 1(-1). Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626434      PMCID: PMC1428039          DOI: 10.1111/j.1365-2125.1983.tb02184.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA.

Authors:  G CRAMER; B ISAKSSON
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  Intramuscular injection of drugs.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

3.  Cerebral malaria.

Authors:  I T Patrick
Journal:  Br Med J       Date:  1968-09-28

4.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 6.  The treatment of severe falciparum malaria.

Authors:  A P Hall
Journal:  Trans R Soc Trop Med Hyg       Date:  1977       Impact factor: 2.184

7.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

  7 in total
  31 in total

Review 1.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

2.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  Effect of dose size on the pharmacokinetics of orally administered quinine.

Authors:  A Sowunmi; L A Salako
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  Divided dose intramuscular regimen and single dose subcutaneous regimen for chloroquine: plasma concentrations and toxicity in patients with malaria.

Authors:  R E Phillips; D A Warrell; G Edwards; Y Galagedera; R D Theakston; D T Abeysekera; P Dissanayaka
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-05

7.  Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria.

Authors:  R E Phillips; S Looareesuwan; N J White; K Silamut; S Kietinun; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

8.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Chalcroft
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

9.  The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.

Authors:  K Na-Bangchang; F Doua; J Konsil; W Hanpitakpong; B Kamanikom; F Kuzoe
Journal:  Eur J Clin Pharmacol       Date:  2004-05-13       Impact factor: 2.953

10.  Quinine distribution in mice with Plasmodium berghei malaria.

Authors:  Eric Pussard; Alexandra Bernier; Elyane Fouquet; Patrice Bouree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.